
Oncology NEWS International
- Oncology NEWS International Vol 18 No 8
- Volume 18
- Issue 8
Yaupon locks up phase II Clearazide trial
Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.
Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.
The randomized study, slated for completion in 2010, has enrolled 260 patients from 13 cancer centers. Clearazide is a topical form of nitrogen mustard, an alkylating agent that works by inhibiting DNA replication.
Articles in this issue
over 16 years ago
New Doxil-based regimens don’t fly with FDA advisorsover 16 years ago
Four steps to improve the profitability of your oncology practiceover 16 years ago
Mathematical model predicts resistance to Herceptinover 16 years ago
ASTRO issues guide on accelerated breast radiotherapyover 16 years ago
Study renews breast ca link to migrainesover 16 years ago
Sutent shows promise for brain metastases in NSCLC patientsover 16 years ago
Abraxane, carboplatin pack one-two punch in two types of lung cancerover 16 years ago
Discord prevails over pt privacy in clinical trialsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































